Jun 9, 2026, 08:17 by

Alithea Genomics has announced a new agreement with Revvity Inc. to broaden access to MERCURIUS™ DRUG-seq and MERCURIUS™ Total DRUG-seq solutions through Revvity’s global commercial network.

Jun 9, 2026, 08:17 by

Nurix Therapeutics and Roche have announced a global collaboration to develop and commercialize bexobrutideg, an investigational BTK degrader designed to treat blood cancers, autoimmune disorders, and neurological diseases. Under the agreement, Nurix will receive a $700 million upfront payment and could earn up to $2.3 billion in additional milestone payments. Bexobrutideg is designed to eliminate the BTK protein rather than simply block its activity, potentially offering advantages over existing BTK inhibitors, including effectiveness against treatment-resistant disease. The partnership will support ongoing late-stage studies in chronic lymphocytic leukemia (CLL) while expanding development into multiple sclerosis (MS) and chronic spontaneous urticaria (CSU), aiming to unlock the therapy’s full potential across multiple disease areas.

Jun 9, 2026, 01:00 by User Not Found

Clinical Research News | In the latest episode of The Scope of Things, Eugene Manley, Jr., founder and CEO of the STEMM & Cancer Health Equity Foundation, explains how underrepresented populations, including Black, Hispanic, Indigenous, rural, low-income, immigrant, underinsured, and uninsured communities, are less likely to receive guideline-aligned biomarker testing and less likely to be asked about clinical trial participation at all.

Jun 8, 2026, 08:14 by

Platform helps manufacturers evaluate sustainability, utilities, and lifecycle costs before committing to major infrastructure

Jun 5, 2026, 07:35 by

AstraZeneca has received FDA approval for Baxfendy, a first-in-class treatment for hypertension, marking a significant milestone in its cardiometabolic growth strategy. The company believes the drug could address a major unmet need among millions of patients with uncontrolled blood pressure and has the potential to generate up to $5 billion in peak annual revenue. AstraZeneca is also evaluating Baxfendy for chronic kidney disease, heart failure, and other related conditions. The approval strengthens the company's position in cardiovascular and metabolic care while supporting its long-term growth ambitions.

Jun 4, 2026, 12:07 by

Moderna and Merck shared 5-year results from the KEYNOTE-942 study showing that their personalized mRNA cancer vaccine, intismeran autogene, combined with KEYTRUDA, significantly improves outcomes for high-risk melanoma patients. The treatment reduced the risk of cancer recurrence or death by 49% and distant metastasis or death by 59% compared to KEYTRUDA alone. It also showed encouraging overall survival trends and stronger immune responses driven by tumor-targeted T-cells. The therapy remained safe over long-term follow-up with mostly mild side effects, highlighting the potential of personalized cancer vaccines in future oncology care.

Jun 4, 2026, 12:07 by

Jun 4, 2026, 12:07 by

Yunu has launched a new De-ID & Export feature that streamlines how clinical research sites share imaging data with trial sponsors. The capability enables sites to securely export images, results, and supporting files while automatically applying study-specific de-identification requirements. By reducing the manual effort typically involved in preparing and transferring trial data, the tool aims to improve operational efficiency, reduce site burden, and accelerate data sharing across clinical studies.

Jun 4, 2026, 01:06 by User Not Found

Clinical Research News | The diagnostics industry is at the intersection of enormous clinical development and technological change, enabling first-ever detection milestones heavily driven by artificial intelligence and multi-biomarker tests. But it has increasingly been coming into conflict with a decades-old regulatory system that didn’t anticipate these technological changes and a political environment that favors U.S. competition and innovation but is also interested in cutting the budget.

Jun 3, 2026, 07:24 by

Aragen has successfully completed the technology transfer and manufactured the first commercial-scale GMP batches of Renaissance Pharma’s Daretabart in just nine months. The humanized monoclonal antibody, which targets high-risk neuroblastoma, recently received FDA Fast Track Designation. Utilizing Aragen’s dual-hub model, production transitioned from early-phase development in Morgan Hill, California, to a new $40 million commercial biologics facility in Bengaluru, India. This strategic collaboration significantly increased the drug's titer, accelerating clinical production toward a future Biologics License Application submission.

Jun 3, 2026, 01:21 by User Not Found

Clinical Research News | VeriSIM Life is building the “full-stack predictive infrastructure” to help pharma companies foresee the challenges ahead in translating a molecule from laboratory discovery to a successful human therapy. The help comes in the form of a dynamic, “credit-score-like” assessment of the risk with inherent explainability and trust.

Jun 2, 2026, 01:01 by User Not Found

Clinical Research News | An analysis released by Phesi suggests that the systematic use of historical protocol templates without using patient data and context to guide protocol design leads to flaws being scaled, rather than solved, by AI.

Jun 1, 2026, 09:50 by

ClearNote Health today announced a $52M Series D financing alongside the appointment of Kevin Keegan as President and COO.

Jun 1, 2026, 09:50 by

CellCarta has announced a Strategic Partnership with Sonic to launch the first commercial laboratory relationship in CellCarta’s Lab Network strategy.

Jun 1, 2026, 09:50 by

Jun 1, 2026, 09:50 by

New START site to be established in collaboration with Baptist Health Herbert Wertheim Cancer Institute will bring novel oncology therapies closer to patients across South Florida.

Jun 1, 2026, 09:50 by

Syncell announced the commercial launch of Syncell Discovery Services, a new sample-to-discovery offering that gives biopharma, translational, and academic researchers direct access to insights generated by the company’s unbiased nanoscopic Microscoop Mint platform.

Jun 1, 2026, 09:50 by

Ahead of BIO San Diego, Shilpa Biologicals urges biotech innovators to engage CDMO partners earlier and look beyond large-scale providers. Over-relying on a narrow network of large CDMOs increases the risk of scope creep, severe clinical trial delays, and budget overruns of up to 40%. Conversely, incorporating smaller CDMOs can lower costs and accelerate timelines from discovery to clinic by several months.

Jun 1, 2026, 09:50 by

Jun 1, 2026, 09:50 by